273 related articles for article (PubMed ID: 9362205)
21. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
Testro AG; Wongseelashote S; Angus PW; Gow PJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
[TBL] [Abstract][Full Text] [Related]
22. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
[TBL] [Abstract][Full Text] [Related]
23. Review article: future indications for terlipressin therapy.
Lebrec D
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():65-7; discussion 68. PubMed ID: 15335406
[TBL] [Abstract][Full Text] [Related]
24. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
25. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
Fimiani B; Guardia DD; Puoti C; D'Adamo G; Cioffi O; Pagano A; Tagliamonte MR; Izzi A
Eur J Intern Med; 2011 Dec; 22(6):587-90. PubMed ID: 22075285
[TBL] [Abstract][Full Text] [Related]
26. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
[TBL] [Abstract][Full Text] [Related]
27. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
Rodríguez E; Elia C; Solà E; Barreto R; Graupera I; Andrealli A; Pereira G; Poca M; Sánchez J; Guevara M; Soriano G; Alessandria C; Fernández J; Arroyo V; Ginès P
J Hepatol; 2014 May; 60(5):955-61. PubMed ID: 24447876
[TBL] [Abstract][Full Text] [Related]
28. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
[TBL] [Abstract][Full Text] [Related]
29. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Ganne-Carrié N; Hadengue A; Mathurin P; Durand F; Erlinger S; Benhamou JP
Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
[TBL] [Abstract][Full Text] [Related]
30. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.
Kim HR; Lee YS; Yim HJ; Lee HJ; Ryu JY; Lee HJ; Yoon EL; Lee SJ; Hyun JJ; Jung SW; Koo JS; Choung RS; Lee SW; Choi JH
Clin Mol Hepatol; 2013 Dec; 19(4):417-20. PubMed ID: 24459647
[TBL] [Abstract][Full Text] [Related]
31. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
Halimi C; Bonnard P; Bernard B; Mathurin P; Mofredj A; di Martino V; Demontis R; Henry-Biabaud E; Fievet P; Opolon P; Poynard T; Cadranel JF
Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
[TBL] [Abstract][Full Text] [Related]
32. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
Testro AG; Angus PW
J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
[No Abstract] [Full Text] [Related]
33. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
34. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis: terlipressin therapy for the hepatorenal syndrome.
Fabrizi F; Dixit V; Martin P
Aliment Pharmacol Ther; 2006 Sep; 24(6):935-44. PubMed ID: 16948805
[TBL] [Abstract][Full Text] [Related]
36. Hepatorenal syndrome in patients with cirrhosis.
Moreau R
J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
[TBL] [Abstract][Full Text] [Related]
37. Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature.
Taşliyurt T; Kutlutürk F; Erdemır F; Yelken BM; Yilmaz A; Kisacik B; Aytan P; Köseoğlu RD
Turk J Gastroenterol; 2012; 23(6):788-91. PubMed ID: 23864457
[TBL] [Abstract][Full Text] [Related]
38. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report.
Vaccaro F; Giorgi A; Riggio O; De Santis A; Laviano A; Rossi-Fanelli F
Dig Liver Dis; 2003 Jul; 35(7):503-6. PubMed ID: 12870738
[TBL] [Abstract][Full Text] [Related]
39. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
Nazar A; Pereira GH; Guevara M; Martín-Llahi M; Pepin MN; Marinelli M; Solá E; Baccaro ME; Terra C; Arroyo V; Ginès P
Hepatology; 2010 Jan; 51(1):219-26. PubMed ID: 19877168
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
